

ondine



For Immediate Release

Ondine Receives Health Canada License for Multi-Purpose Photodisinfection Laser

Vancouver, Canada – June 4 2008 - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP), a medical technology company announces that it has received a Health Canada license for a next-generation multi-purpose laser system that is suitable for a broad range of applications in high volume settings, such as hospitals and large institutions. This system will initially be directed towards decolonization of potentially pathogenic bacteria such as *S. aureus* and MRSA in the nose, as well as for the decolonization of microorganisms from other sites.

Photodisinfection utilizes photoactive agents and light sources to effect potent, broad-spectrum disinfection across a variety of dental, medical and other applications. The Company's photodisinfection laser is expected to provide an alternative resource to antibiotics for clinicians and patients in the eradication of *S. aureus* and resistant 'superbugs' including MRSA. According to the Centers for Disease Control and Prevention (CDC), antibiotic resistance has become 'one of the world's most pressing public health problems'.

"With rates of hospital-acquired infections and antibiotic resistance rising steeply, it is imperative that non-antibiotic, anti-infective therapies are developed," stated Carolyn Cross, Ondine's President and CEO. "Many hundreds of clinicians in Canada and the European Union are successfully using our Periowave™ photodisinfection technology for the treatment of periodontal disease. We believe that this technology may be capable of addressing many other clinically unmet needs where a broad-spectrum, safe, non-antibiotic therapy is required. We intend to commercialize additional applications of our versatile photodisinfection platform through strategic partners, leveraging in-house expertise in rapid product development, regulatory affairs and existing sales and marketing channels."

About MRSA and Antibiotic Resistance

The MRSA 'superbug' has become resistant to most antibiotics. Approximately 95% of all patients with an MRSA infection do not respond to first-line antibiotics. If the bacterium enters the bloodstream, nearly half of these critically ill patients will die despite access to potent antibiotics. Healthy people (including hospital healthcare workers) carry MRSA bacteria in their noses and on the skin, and inadvertently pass it on to others or self-infect by sneezing, breathing, or by touch-based transfer.

More than two million hospital-acquired infections occur each year in the U.S. Antibiotic resistance is becoming a growing concern; it is crucial that new non-antibiotic modalities to fight bacterial infections are developed. Over the last decade, almost every class of bacteria has become less responsive to antibiotics and the burden on the healthcare system related to treating antibiotic resistant infections exceeds \$8 billion in both the U.S. and U.K. It is estimated that the annual cost associated with treating MRSA in the U.S. is approximately US\$4 billion.

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, and an international office in St Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION please contact:

Carolyn Cross
President and
Chief Executive Officer
Ondine Biopharma Corporation
(604) 669-0555
ccross@ondinebiopharma.com

Christina Bessant
Investor Relations
The Equicom Group Inc.
(416) 815-0700 ext. 269
cbessant@equicomgroup.com

Canaccord Adams Ltd
Nominated Adviser &
Broker
Neil Johnson /
Ryan Gaffney
+4420 7050 6500